

Special Issue

Multiple Sclerosis, Complications and Therapeutics 2.0

Message from the Guest Editors

For improved MS treatments it is relatively weak as compared to other CNS disorders, although there are a number of different drug classes in development including;

- Monoclonal Antibodies - to block destructive immune cells entering brain and spinal cord
- Immunosuppressant's - suppress immune system and prevent myelin damage
- Potassium channel blockers - improve the conduction of demyelinated fibers
- Protein growth factors - to limit demyelination and oligodendrocyte injury
- Immunotherapy / Vaccines - to switch immune response to protect neurons and prevent demyelination

This special issue is now open and is seeking research papers and reviews on MS therapeutics from animal models to human clinical studies, and MS complications and side effects of certain therapeutics.

Guest Editors

Prof. Dr. Vasso Apostolopoulos

Dr. Narges Dargahi

Dr. Jack Feehan

Deadline for manuscript submissions

closed (30 October 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/81367

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).